TOPOTECAN
Background and Date of Approval
Topotecan is indicated for treating recurrent ovarian and lung cancers that have recurred following completion of chemotherapy. In advanced cervical cancer where surgery or radiotherapy is ineffective, topotecan is used in combination with cisplatin. Paediatric use is not recommended. Patients should avoid grapefruit and grapefruit juice during topotecan treatment, as consumption may increase drug concentration in the body and heighten the potential for adverse effects. Topotecan received initial FDA approval on 14 October 1996 for advanced ovarian cancer with recurrence following treatment. Subsequently, the FDA has approved topotecan for additional cancer types, including small cell lung cancer and cervical cancer. The therapeutic benefits in cancer treatment often outweigh potential side effect risks, and many patients have achieved favourable outcomes with this treatment.
Uses
Topotecan is an important medication used in the treatment of various types of cancers, including ovarian, small-cell lung, and cervical cancers.
How is it administered?
Topotecan is typically administered by a healthcare provider as an intravenous (IV) infusion in a clinical setting. The dosage and frequency of infusions will vary depending on the patient's individual medical condition, age, weight, and other factors. You should not take a double dose to make up for the second dose.
Side Effects
Topotecan, like many chemotherapy drugs, can cause a range of side effects. Common side effects include nausea, vomiting, diarrhea, fatigue, hair loss, and decreased appetite. More serious side effects may include bone marrow suppression, gastrointestinal toxicity, lung toxicity, neurological toxicity, cardiac toxicity, allergic reactions, and liver toxicity. Patients should be vigilant for any new or worsening symptoms and report them to their healthcare provider immediately.
Warnings
Topotecan can cause bone marrow suppression, which may lead to a decrease in the number of white blood cells, red blood cells, and platelets in the blood. This can increase the risk of infection, anemia, and bleeding. Because of bone marrow suppression, patients receiving treatment may be at increased risk of infection. There is a small risk of developing secondary malignancies, including leukemia, after treatment with this medication. Patients with pre-existing kidney impairment or elder patients may have a higher risk of developing serious side effects from this medication. This medication can also cause cardiac toxicity, including changes in heart rate and blood pressure. In rare cases, neurological toxicity, including peripheral neuropathy and cognitive impairment can occur after taking this medicine. It can also cause skin reactions, including rash and photosensitivity.
Precautions
Patients with pre-existing cardiac conditions and renal problems should monitor kidney and heart function regularly before and while taking Topotecan. Patients should have their blood counts monitored regularly during treatment. Patients should avoid contact with people who have infections, practice good hygiene, and report any signs of infection to their healthcare provider. Tell your doctor immediately about any new or worsening neurological symptoms. Patients should avoid excessive sun exposure and use sunscreen during treatment.
Word of Advice
Report any side effects or concerns to your doctor promptly while receiving Topotecan treatment. If you are pregnant, planning to become pregnant, or breastfeeding, discuss the risks and benefits with your healthcare provider. Women of reproductive age should use effective contraception during treatment and for at least two weeks after the final dose. Avoid grapefruit consumption while taking this medication, as it reduces drug absorption and may cause severe side effects. Protect your skin from sun exposure during treatment. Lifestyle modifications such as smoking cessation, maintaining a healthy weight, and consuming a balanced diet can support overall health and reduce the risk of complications associated with cancer. Emotional support from family, friends, or support groups can help patients manage the demands of cancer treatment.
References
Accord Ltd, US Food & Drug Administration, [Revised on Sep 2018] [Accessed on 24th April 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020671s023lbl.pdf Edward Chu, Cancer Chemotherapy, Langeâs Basic and Clinical Pharmacology, 14th Edition, 2018, 948-976
Frequently Asked Questions
Can topotecan be given to elderly patients?
Yes, topotecan can be given to elderly patients. However, elderly patients may be at higher risk of certain side effects, such as bone marrow suppression and gastrointestinal toxicity. The dosage may need to be adjusted for elderly patients.
How Topotecan will affect my blood?
Topotecan can affect your blood count by decreasing the number of white blood cells, red blood cells, and platelets in your blood. This can increase the risk of infections, anemia, and bleeding. Your healthcare provider will monitor your blood counts regularly during treatment and may adjust your dosage or delay treatment based on your blood count results.
What can I do to manage gastrointestinal toxicity caused by Topotecan?
Your healthcare provider medications to help manage nausea, vomiting, and diarrhea caused by topotecan. You can also try eating small, frequent meals and drinking plenty of fluids to help alleviate these symptoms.
Can topotecan cause fertility problems?
Topotecan may affect fertility in both men and women. Patients should discuss their options for preserving fertility with their healthcare provider before starting treatment.
Can topotecan cause nerve damage?
Topotecan can cause nerve damage, which may lead to symptoms such as tingling, numbness, or weakness in the hands and feet. Patients should notify their healthcare provider if they experience any new or worsening neurological symptoms.